Scientific output on coronavirus and WHO's Solidarity Project: a science-based choice?

In March 2020, the World Health Organization (WHO) launched the Solidarity Program probably the largest global initiative to encourage and support research in four promising drugs and therapies (Remdesivir, Hydroxychloroquine, {beta} interferon and the combination Lopinavir / Ritonavir) to reduce the mortality of COVID-19. Considering the potential impact of this project to restrain the current pandemic, the present study aims to investigate whether it was designed upon a scientific basis. For this proposal, we collected all documents on coronavirus indexed in Scopus database by using a search strategy based in MESH terms. Among the studied groups of documents, we looked in more detail the Coronavirus group in order to find documents related to WHO's drugs or to other drugs and therapies extracted from another source. The main findings indicate that the number of documents related to WHO's drugs are higher than in the other groups and this subset of documents involves a larger number of institutions and countries. Hence, the results shown in this study illustrate that decisions by an international body, as WHO, may be science-based and not be merely bureaucratic decisions.

CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 18, 2020. ;https://doi.org/10.1101https://doi.org/10. /2020 7 -Group Gammacoronavirus: gammacoronav* OR "Gamma coronav*" OR "Bluecomb 1 4 1 Vir*" OR ("Transmissible Enteritis Vir*" W/2 turkey*) OR ("Enteri* Vir*" w/3 1 4 2 Turkey) OR ("bronchit* vir*" W/1 infect*); 1 4 3 Data collection was carried out on May 30, 2020 at the Scopus database, due to  The totals of retrieved documents in the four groups were: 2,719 documents on 1 4 9 1 7 9 "mvamers-s", "mrna 1273" or "mrna-1273". All these terms were searched in the 1 8 0 abstract, document title and database and author keywords.  In order to verify whether the most prolific institutions among documents on COVID-19, in 23 July, 2020, we collected the list of agreements in progress catalogued 1 9 0 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 18, 2020. ;https://doi.org/10.1101https://doi.org/10. /2020 by Cortellis, a database of Clarivate Analytics. By searching the term "coronavirus 1 9 1 infection", we have found 2,226 agreements, which encompass 186 institutions, 766 1 9 2 drugs and 879 patents. Data on agreements were downloaded in a Microsoft Excel 1 9 3 format and all agreements dealing with drugs and therapies were identified as following. Agreements classified as WHO's drugs were identified by having the following 1 9 5 terms: hydroxych, remdesivir, lopinavir, ritonavir, "interferon beta", "beta interferon", 1 9 6 interferonbeta and betainterferon. As for agreements on Other drugs, we used the words 1 9 7 darunavir, cobicistat, chloroquine, danoprevir, diammonium, glycyrrhizinate, 1 9 8 favipiravir, leronlimab and oseltamivir. As for agreements classified as antibody and 1 9 9 vaccine were identified, respectively, by containing at least one of the terms (a) 2 0 0 sarilumab, "regeneron 3048", "regn 3048", regn3048, regn-3048, "regeneron 3051", 2 0 1 "regn 3051", regn3051, regn-3051, sab-301, "sab 301", sab301 and siltuximab and (b) 2 0 2 gls5300, gls-5300, "gls 5300", chadox1, mva, "mrna 1273" and mrna-1273. The and countries was then calculated. The sum of the documents classified in all four studied groups duplication is 31,815. This amount is distributed in the following typologies: 68% 2 1 0 article or article in press, 10% article review, 7% letter, 5% editorial, 4% note, 3% 2 1 1 conference paper or review, 1% book, 1% short survey and 1% data paper, erratum or 2 1 2 retracted. In the following sections, we present the results regarding (a) general data, . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 18, 2020. ;https://doi.org/10.1101https://doi.org/10. /2020 1 0 (b) a subset of data on Coronavirus groups related with drugs and other therapies as well 2 1 6 as their leading institutions and countries. The number of documents on coronavirus classified under the four main groups 2 2 0 by decades is shown in Figure 2. As can be seen, the number of documents found in the 2 2 1 1940s and 1950s is residual, either because of the database's low journal coverage in 2 2 2 these decades or because research on coronavirus was still incipient at that time. In the 1940s, we found the first document on coronavirus registered in Scopus: a 2 2 8 paper entitled "Demonstration of an interference phenomenon associated with infectious 2 2 9 bronchitis virus (IBV) of chickens", that is, a clear example of document related to one 2 3 0 of the main MeSH terms related to Gammacoronavirus. As for the following decade, we 2 3 1 found 18 documents in the Betacoronavirus group, being none of them related to human 2 3 2 coronavirus but to hepatitis virus either in mouse or mice, which is in accordance to 2 3 3 MeSH terms indicated to this family. From 1960s to 2020s, there was a strong growth trend in the number of 2 3 5 documents related to most groups, specially the Coronavirus group (gray bar). Documents of this group increased from 89 to 9,179, that is, a growth rate of 102.1 in 2 3 7 the period. Considering the total of documents indexed at Scopus database, these totals 2 3 8 represent 0.00% and 0.44%, respectively, which signals a real increase in this theme in 2 3 9 the set of documents in the database.
CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 18, 2020. ; https://doi.org/10.1101/2020.11.16.20232488 doi: medRxiv preprint 1 1 The total of documents related to the three coronavirus genera also indicates 2 4 1 growth over the periods, except for 2020 in the groups of Alphacoronavirus (blue bar) 2 4 2 and Gamacoronavirus (black bar), being the latter not associated with humans. The total 2 4 3 number of documents in these two groups increased, respectively, from 9 to 1,492 (a Gamacoronavirus are 18.17% and 12.81% respectively. notable increase over the period, which seems to take place in two phases: from 1960 to  As the Coronoravirus group (n. 28,013) display the largest number of 2 6 3 documents, we decided to investigate some parameters to better characterize it. In this 2 6 4 section, we present the distribution of these documents according to the type of research 2 6 5 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 18, 2020. ; https://doi.org/10.1101/2020.11.16.20232488 doi: medRxiv preprint 1 2 application they are related with, that is (a) diagnosis, (b) treatment or (c) vaccine, a 2 6 6 typology is supported by Tarik Jasarevic (33). The analysis was carried out considering 2 6 7 a Venn diagram (Figure 3), which makes it possible to identify the intersections 2 6 8 between the three types of applications. We found that, over the period of analysis, the scientific community on 2 7 3 coronavirus has been dedicating more efforts to research related to treatment (n. 5,947).

7 4
The documents in this group, in general, include controlled studies with antiviral agents 2 7 5 or with some other drugs to reduce or combat symptoms related to the disease.   . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 18, 2020. ; https://doi.org/10.1101/2020.11.16.20232488 doi: medRxiv preprint 1 3 2 9 1

Drugs and other therapies among documents on coronavirus group
In this section, we identify and compare the number of documents on 2 9 3 Coronavirus group (n. 28,013) related to two groups of drugs and to a group of 2 9 4 Antibody, both with the potential for use in the treatment of COVID-19 patients. We 2 9 5 also analyzed the documents on coronavirus related to a group of vaccines, which 2 9 6 makes a counterpoint to the groups of drugs and Antibody, since it is generally a 2 9 7 preventive method for avoid spreading the disease. Figure 4 presents the number of 2 9 8 documents on coronavirus by decade according to the group of drugs or other therapies. As a first observation, we draw attention to the low number of documents in the four 3 0 0 groups, which adds up to 908 between 1980 and 2020, that is, a share of 3.24% of the 3 0 1 total documents on Coronavirus group published in the period. As can be noted, WHO drug-related documents (red bar), that is, those indicated  From the 2010s on, it is noted an increase in documents related to other drugs 3 1 2 (orange bar) and antibody (dark blue). We believe that such increase is due to the . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 18, 2020. Curiously, we did not observe a similar trend among documents related to 3 1 7 vaccines (light blue). The low and reducing number of these documents in the last 3 1 8 decades may be a consequence of the complex process that developing a vaccine is,  For a better understanding of the nature of the four groups of drugs and other 3 2 2 therapies, Table 1 presents the name of the compound and its respective number of   . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 18, 2020. ; https://doi.org/10.1101/2020.11.16.20232488 doi: medRxiv preprint 1 5 Within the group WHO's drugs, documents referring to a drug named Interferon 3 2 9 beta are the majority (n. 331), while those related to Hydroxychloroquine sulfate, which 3 3 0 was widely propagated by some global representatives (34) as a potential treatment for 3 3 1 COVID 19, are the least frequent (n. 13) in this group.

2
Regarding the group Other drugs, we found documents on coronavirus related to  vaccine that uses plasmid DNA to express the MERS-CoV spike glycoprotein.  In Table 2, we first present a general analysis, where the number of documents  CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 18, 2020. ; https://doi.org/10.1101/2020.11.16.20232488 doi: medRxiv preprint 1 drugs are distributed almost equally among the three categories of number institutions.

5 7
Documents with two or more institutions sum 482 and 70, which represent 64.1% and 3 5 8 67.3% in both groups, respectively. As for documents in Antibody and Vaccine, we 3 5 9 note a quite different trend, especially the latter, with 80% of the documents signed by As for the agreements on coronavirus, that is the Cortellis dataset, we did not  However, we noted a low level of institutional and country diversity, especially among number of agreements is related to Others drugs rather than to WHO's drugs while the 3 7 0 lowest number of agreements is related to Antibody and not to Vaccine.

7 1
In order to better understanding whether institutions are involved in the research 3 7 2 on coronavirus and in the development of a treatment to prevent or to seek the cure for and agreements according to the groups of drugs and therapies (Table 3). . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review) preprint
The copyright holder for this this version posted November 18, 2020. ; https://doi.org/10.1101/2020.11.16.20232488 doi: medRxiv preprint 2  (4) CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review) preprint
The copyright holder for this this version posted November 18, 2020. ;https://doi.org/10.1101https://doi.org/10. /2020 Among Scopus documents, we observed the predominance of institutions from universities also stand out in these groups, but are not listed in the others groups, they institutions that are listed in more than one group, apart those mentioned before, we  In the group Antibody, the leadership is with Columbia University. This group    . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review) preprint
The copyright holder for this this version posted November 18, 2020. ;https://doi.org/10.1101https://doi.org/10. /2020 4 Among the private companies, we highlight the following: (a) in the group 4 0 7 WHO's drugs, the Gilead Sciences Inc that is investigating the drug Remdesevir (35), ModeRNA Therapeutics that is developing the mRNA-1273 vaccine, which is also in 4 1 1 phase 3 clinical trial (37).    CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 18, 2020. ; https://doi.org/10.1101/2020.11.16.20232488 doi: medRxiv preprint 5 4 3 2 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Considering the agreements (Figure 6), the United States once again stands out, countries from all continents, as we observed in Figure 5 for group WHO's drugs. Comparing each group in Figures 5 and 6, we noted that countries are found in  CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 18, 2020. ;https://doi.org/10.1101https://doi.org/10. /2020 2 The present study aims to investigate whether the drugs indicated by WHO's  Hence, considering these two characteristics, we do believe in the originality, 4 6 7 robustness and reliability of the data presented in our paper.

6 8
Among the general findings, we observed a continuous growth over the decades groups to beta.

7 5
As Coronavirus group encompasses documents of other groups, we considered it 4 7 6 as our main source to carry on the following analyzes, including the analysis related to 4 7 7 type of research application (Figure 3). With respect to this analysis, we found that the while those associated to epidemiology are the most frequent, that is 37.2%.
CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 18, 2020. ; https://doi.org/10. 1101/2020 3 Nevertheless, such discrepancy may be a consequence of the low number of In a second part of our study, that is its core part, we presented findings on drugs are still in the agenda of global science, but recent results suggest they are as not 4 9 5 as much promising in curing or reducing mortality by . Despite these 4 9 6 disappointments, experts have pointed to many benefits that arose with this big project to the already existing scientific capital and structure in such institutions. It is clear that, Solidarity Project was designed upon a scientific basis. A choice of other drugs that had 5 0 7 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 18, 2020. ; https://doi.org/10. 1101/2020 4 no or very few involvements of institutions and countries would demand a more 5 0 8 complex logistic and training and probably it would be more costly.

0 9
Our data showed that China and USA share the leadership on coronavirus nations do also stand out among the top ranked countries in terms of agreements to 5 1 6 develop therapies against the coronavirus ( Figure 6). Nevertheless, we observed a 5 1 7 smaller number of countries signing these agreements, that is, a completely different  therapies that are taking part in ongoing research would be a hard (or impossible) task.

2 6
In any case, we believe that the data shown in this study illustrates that decisions by 5 2 7 international organizations, especially in health, may have scientific knowledge as a 5 2 8 background and not be merely bureaucratic decisions. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 18, 2020. ; https://doi.org/10.1101/2020.11.16.20232488 doi: medRxiv preprint

1.
World Health Organization [Internet]. COVID-19 Questions and answers. Egypt  Deltacoronavirus Supports Bat Coronaviruses as the Gene Source of 5 5 6 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 18, 2020. ; https://doi.org/10. 1101/2020